Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women.
The minimum dosage of transcutaneous hormone replacement therapy (HRT) able to exert protective effects on postmenopausal bone mass, especially in older women, is uncertain. This study investigates the effects of transcutaneous HRT at two different doses of oestradiol [Estraderm 25 and 50 (E25, E50)] over 2 years in 44 postmenopausal women younger than 67 years and 27 of 67 years and older. Circulating biochemical markers of bone and connective tissue turnover, collagen type I (intact PINP, PICP) and type III (PIIINP) propeptides and type I telopeptide (ICTP), osteocalcin (OC) and alkaline phosphatase (AP) were measured. The responses of the biochemical markers in all the groups were very similar, and most of the observed changes occurred within the first year of treatment. E25 had an effect on the bone markers similar to that of E50, and there was little difference in response according to the patient's age. PINP fell markedly after 1 year in all groups to about half the pretreatment level, with a smaller drop in the second year. PICP responded more variably, and mean values were little changed. There was a slight fall at the higher dose in the younger women, and also in the older women (whose baseline level was higher) on the lower dose. The correlation between PINP and PICP was 0.52 at pretreatment and 0.84 after 2 years of treatment. PIIINP showed no changes. OC and AP both fell in all groups by the first year, but less markedly than PINP. Their response was slightly less pronounced in the older women. ICTP fell marginally in the younger women, and only after 2 years, regardless of dose. Postmenopausal serum oestradiol levels increased after HRT and were associated with decreased binding globulin (SHBG) levels in all groups. After E25 patch application individual serum oestradiol levels were variable and peaked between 13 and 36 h with a median value of 83.8 pmol L-1. Our data suggest that low-dose transcutaneous HRT restores circulating oestradiol levels in postmenopausal osteopenic women of all ages as effectively as conventional-dose HRT and is associated with decreased circulating markers of bone and connective tissue turnover.
Sharp
C A
CA
Charles Salt Centre, Robert Jones & Agnes Hunt Orthopaedic and District Hospital NHS Trust, Oswestry, Shropshire, UK.
Evans
S F
SF
Risteli
L
L
Risteli
J
J
Worsfold
M
M
Davie
M W
MW
D000279:Administration, Cutaneous; D000367:Age Factors; D000368:Aged; D000469:Alkaline Phosphatase / Q000032:analysis; D000943:Antigens, Differentiation; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D001842:Bone and Bones / Q000378:metabolism*; D003094:Collagen / Q000032:analysis / Q000378:metabolism; D024042:Collagen Type I; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000032:analysis; D010455:Peptides / Q000032:analysis; D017698:Postmenopause / Q000378:metabolism*
D000943:Antigens, Differentiation; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D004958:Estradiol; D003094:Collagen; D000469:Alkaline Phosphatase